Nevada Consortium on Dementia Research

The Nevada Consortium on Dementia Research is a membership group open to Nevada institutions with an interest in developing collaborative research, education and public service programs for people living with dementia. To learn more or participate in their studies, click here.

The mission of the Nevada Research Consortium on Dementia is to advance our knowledge of care and support of Alzheimer’s disease and other dementias through fostering research activities in Nevada.

The NRCD accomplishes this mission by:

  • Promoting and expanding research opportunities and collaborations throughout Nevada related to Alzheimer’s disease and other dementias.
  • Disseminating emerging findings through multiple venues to educate providers and patients.
  • Informing evidence-based practices and policies.
  • Encouraging new researchers to join this field of investigation

To see upcoming meetings click here.

Research Studies

EXERT

EXERT

What is the EXERT Study? EXERT is a national, 18-month long, clinical trial to test whether physical exercise can slow the progression of early Alzheimer’s disease related memory problems or mild cognitive impairment in older adults. EXERT is taking place at 15...

read more
CREAD 2

CREAD 2

What is the CREAD 2? A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD). This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety...

read more
The Generation Program

The Generation Program

What is the Generation? The Generation Program is made up of two clinical trials: Generation Study 1 and Generation Study 2. Each trial will last for 5 – 8 years and will be investigating treatment that may be able to prevent the onset of Alzheimer’s. We’ll have many...

read more
ADNI3

ADNI3

What is the ADNI3? For the last 12 years the Alzheimer's Disease Neuroimaging Initiative has enrolled more than 800 patients and lead to significant advances in our understanding of Alzheimer's Disease.  Now in its 3rd iteration, ADNI3 will advance our understanding...

read more
NILO-PD

NILO-PD

What is the NILO-PD? The Parkinson Study Group (PSG), under the direction of Tanya Simuni, MD (Northwestern University) is conducting a multi-center, randomized, double-blind, placebo-controlled study of nilotinib in individuals with Parkinson’s disease...

read more
Elko Washoe Winnemucca/Humboldt Clark Nye Lincoln White Pine Esmeralda Eureka Lander Pershing Churchill Storey Carson City Douglas Lyon Mineral